Myocardial Infarction With ST-Elevation (MISTRAL)
Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring Myocardial infarction, Angioplasty, Coronary stenting, Abciximab, Myocardial reperfusion, Microcirculation, EKG, ST elevation myocardial infarction within 6 h of symptom onset
Eligibility Criteria
Inclusion Criteria:
- Patients over 18 years of age eligible for randomization in the MICU
- Infarct within 6 hours from symptoms onset
- Continuous typical chest pain symptoms symptoms for more than 20 min. and-ST segment elevation of more than 2 mm in more than two leads (peripheral or precordial)
- Signed informed consent form
Exclusion Criteria:
- Ventricular conduction anomalies masking signs of ischemia (left or right bundle branch block without evidence of additional elevation), electrical left ventricular hypertrophy
- Known hypersensitivity to Abciximab or to any component of the product or to murine monoclonal antibodies.- Hemorrhagic diathesis, internal hemorrhage
- Hemorrhagic stroke within 2 years
- Ischemic stroke within the last 3 months- Intra-cranial neoplasm, intracranial malformation or arteria
- venous aneurysm
- Recent intracranial or intraspinal surgery or trauma (within two months)
- Recent within (2 months) major surgery- Known peptic ulcer or upper gastrointestinal bleeding within the previous 6 month
- Known coagulation anomaly
- Oral anti-coagulant or low molecular weight heparin treatment- Ongoing thrombolytic treatment
Sites / Locations
- Service de Cardiologie - Hôpital de Hautepierre - 1, Avenue Molière
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
1
2
Early Abciximab bolus during prehospital transportation in ambulance 0.25 mg/Kg iv with Heparin 40 UI/kg bolus. Abciximab placebo bolus and Abciximab infusion 10 µg/Kg/min after coronary angiography and before angioplasty.
Abciximab placebo bolus during prehospital transportation in ambulance with Heparin 40 UI/kg bolus. Abciximab 0.25 mg/Kg bolus after coronary angiography and before angioplasty followed by Abciximab infusion 10 µg/Kg/min.